company background image
DARE

Daré Bioscience NasdaqCM:DARE Stock Report

Last Price

US$1.25

Market Cap

US$106.0m

7D

0.4%

1Y

-22.8%

Updated

06 Feb, 2023

Data

Company Financials +

Daré Bioscience, Inc.

NasdaqCM:DARE Stock Report

Mkt Cap: US$106.0m

DARE Stock Overview

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women’s health in the United States.

DARE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Daré Bioscience, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Daré Bioscience
Historical stock prices
Current Share PriceUS$1.25
52 Week HighUS$1.88
52 Week LowUS$0.82
Beta1.19
1 Month Change28.21%
3 Month Change35.84%
1 Year Change-22.84%
3 Year Change-2.34%
5 Year Change-55.20%
Change since IPO-79.17%

Recent News & Updates

Recent updates

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02
Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26
We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22
Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dare Bioscience EPS misses by $0.06

Nov 12

Shareholder Returns

DAREUS PharmaceuticalsUS Market
7D0.4%-0.5%1.7%
1Y-22.8%4.6%-9.6%

Return vs Industry: DARE underperformed the US Pharmaceuticals industry which returned 4.6% over the past year.

Return vs Market: DARE underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is DARE's price volatile compared to industry and market?
DARE volatility
DARE Average Weekly Movement8.3%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: DARE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: DARE's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a24Sabrina Johnsonhttps://www.darebioscience.com

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women’s health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company’s product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Daré Bioscience, Inc. Fundamentals Summary

How do Daré Bioscience's earnings and revenue compare to its market cap?
DARE fundamental statistics
Market CapUS$106.03m
Earnings (TTM)-US$24.55m
Revenue (TTM)US$10.00m

10.6x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DARE income statement (TTM)
RevenueUS$10.00m
Cost of RevenueUS$100.00k
Gross ProfitUS$9.90m
Other ExpensesUS$34.45m
Earnings-US$24.55m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin99.00%
Net Profit Margin-245.47%
Debt/Equity Ratio0%

How did DARE perform over the long term?

See historical performance and comparison